Navigation Links
Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
Date:11/6/2007

ael, reported the results of a prospective population-based study of more than 3,000 individuals age 55 or older with diabetes mellitus, who were tested for Hp type and followed for two years in a registry. It was observed that Hp2-2 was associated with a highly significant increase in incidence of non- fatal-myocardial infarction, stroke and cardiovascular death and that only patients with the Hp2-2 genotype (as compared to patients with genotypes Hp1-2 or Hp1-1) were shown to have a significant decrease in major cardiovascular events if their HbA1c was maintained below 7.0, the generally recommended target for tight glycemic control.

The study concluded that to optimize healthcare resource utilization, cardiovascular risk factor modification in individuals with diabetes mellitus should be focused on those patients exhibiting the Hp2-2 genotype (40% of the population). Synvista is developing a diagnostic kit for the detection of Hp type. Until that kit has completed development and becomes available for marketing, physicians or patients may order Hp genotyping from ARUP Laboratories, a Synvista licensee in Salt Lake City, Utah.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is d
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Texas , March 30, 2015  Caris Life ... found drugs targeting specific pathways may have potentially significant ... cancer. The study results were highlighted today in an ... of Gynecologic Oncology (SGO) 2015 Annual Meeting on Women,s ... This study is one of four presented at ...
(Date:3/30/2015)... 2015 NiQ Health, "the ... the high level interface capabilities of their CarePlus™ ... The partnership between CarePlus™ and ClinicAll ... allows patients to choose the most appropriate alarm ... The advanced functionality of CarePlus™ allows patient alarms ...
(Date:3/30/2015)... 30, 2015 DURECT Corporation (Nasdaq: ... a multi-dose Phase 1 clinical trial of an ... DURECT,s Epigenomic Regulator Program.  DUR-928 is an endogenous, ... broad applicability in metabolic diseases such as nonalcoholic ...  It may also play an important role in ...
Breaking Medicine Technology:Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 2Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 3Caris Life Sciences' Multiplatform Tumor Profiling Enhances Understanding of Molecular Drivers and Treatment Selection in Uterine Carcinomas 4NiQ Health Announces CarePlus(TM) Integration with ClinicAll 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4
... (Nasdaq: MYL ) today commented on the death of ... Mylan Chairman and CEO Robert J. Coury said: "We ... one-of-a-kind individual. Mike was a pioneer in many ways and helped ... of us who knew Mike personally will always remember him as ...
... urging the U.S. Department of Health and Human Services ... affordable, flexible benefits in the exchanges, the Institute of ... and some powerful special interests that benefit from costly ... (PCMA). A new survey ...
Cached Medicine Technology:PCMA on IOM Essential Health Benefits Report: Employers and Special Interests Will Spar Over Costly Prescription Drug Mandates 2
(Date:3/31/2015)... Miraca Life Sciences, the nation’s largest independent anatomic ... pathology offering , to include critical testing for both ... pathology services feature:, Definitive diagnoses ... terminology and diagnostic criteria , Quantitative prognostic ... , Molecular tumor profiling , ...
(Date:3/31/2015)... TX (PRWEB) March 31, 2015 ... independent freestanding emergency rooms in the United States, announced ... April. , “I am pleased to announce that ... Worth metroplex in Haslet,” said Dr. James M. Muzzarelli, ... , First Choice Emergency Room is revolutionizing the delivery ...
(Date:3/31/2015)... Buffalo, NY (PRWEB) March 31, 2015 ... been recognized by peers across the country for distinguished ... profession. The New York State Athletic Trainers’ Association ... extend congratulations to these NYS athletic trainers - especially ... (NATM)! The Ed Block Courage Award for ...
(Date:3/30/2015)... (PRWEB) March 31, 2015 A new ... aid patients and family members who may have been ... pregnancy for morning sickness. The site was created in ... of GlaxoSmithKline in C.A. No. 11-10398-RWZ, filed with the ... Toronto Star reports that this case alleged that ...
(Date:3/30/2015)... 31, 2015 NAPW honors ... Woman of the Year. Ms. Lucht is recognized with ... largest, most-recognized networking organization of professional women in the ... Association of Professional Women is a powerfully vibrant networking ... Chapters. , “Today’s managers need to have leadership skills ...
Breaking Medicine News(10 mins):Health News:Miraca Life Sciences Formalizes and Expands Breast Pathology Business 2Health News:Miraca Life Sciences Formalizes and Expands Breast Pathology Business 3Health News:First Choice Emergency Room to Open New Facility in Haslet, Texas 2Health News:NYS Athletic Trainers' Association Congratulates Buffalo Bills Athletic Training Staff for National Award 2Health News:NYS Athletic Trainers' Association Congratulates Buffalo Bills Athletic Training Staff for National Award 3Health News:Robert Gardner Law Announces Resource Site for Patients Prescribed Zofran During Pregnancy 2Health News:National Association of Professional Women Announces Winifred K. Lucht, Patient Financial Services Manager at Marshfield Clinic, a 2015 Professional Woman of the Year 2
... June 15 (HealthDay News) -- Being depressed doesn,t reduce ... finds. University of Michigan researchers analyzed data from ... and found that patients who were depressed or depression-free ... their excess weight within one year. They also reported ...
... Regionals 1st Middle-East & Africa Osteoporosis Meeting, to ... published its scientific programme at , http://www.iofbonehealth.org/dubai-2011/programme.html ... offering awards of 1000 USD each for the top ... age. The abstract deadline is June 17, 2011; all ...
... Researchers at the University of Toronto are the ... sleep disorder that has been closely linked to Parkinson,s ... the first to establish a potential genetic link to ... because between 60 and 80 per cent of people ...
... rock stars of the rodent world, the flashiest performers of ... the ladies, a University of Florida study shows. Neotropical ... a bravura performance attracts more interest from females, according to ... Animal Behaviour by doctoral candidate Bret Pasch and colleagues ...
... An evaluation of the Public Health Grid (PHGrid) technology ... capabilities of epidemiologists and disease-control agencies when the next ... the International Journal of Grid and Utility Computing ... Centers for Disease Control and Prevention, in Atlanta, Georgia, ...
... and women who get just six hours of sleep each night ... from the cumulative effects of this mild sleep deprivation, a new ... able to cope with and recover from this kind of sleep ... the weekend after a busy workweek associated with mild sleep loss ...
Cached Medicine News:Health News:Weight-Loss Surgery Can Be Effective Despite Depression 2Health News:Program announced for 1st Middle-East & Africa Osteoporosis Meeting 2Health News:Potential cause of severe sleep disorder discovered, implications for Parkinson's disease 2Health News:UF study: When singing mice choose a mate, a skillful song gets the gal 2Health News:UF study: When singing mice choose a mate, a skillful song gets the gal 3Health News:A grid approach to pandemic disease control 2Health News:Weekend Not Long Enough to Recover From Workweek Sleep Loss 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: